INTRODUCTION
Fenofibrate, chemically is 2-[4-(4-ch lorobenzoyl) phenoxy]-2-methyl p ropanoic acid 1-methyl ethyl ester 1, 2 . It is the lipid regulating drug (BP 2009). Fenofibrate increases lipolysis and elimination of trig lyceride-rich particles fro m plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity) 3 . It is official in BP 4 . Literature survey revealed that HPTLC 5 HPLC 6 and Stability Indicating UPLC 7 Method for simultaneous determination of Atorvastatin, Fenofibrate and their degradation products in tablets were reported. Also HPLC method has been reported for determination of Fenofib rate in human serum [8] [9] [10] and urine 11 .The present study describes the development and validation of a simple, specific, accurate and precise UVspectrophotometric method for determination of Fenofibrate in pharmaceutical dosage forms. Preliminary solubility studies of Fenofi brate [12] [13] [14] [15] : solubilities of Fenofibrate were determined in 4 M sodium acetate and 1.25 M sodium cit rate solution, distilled water sufficient excess amount of drug was added to screwcapped glass vials of 20 ml capacity, containing distilled water, and 4 M sodium acetate and 1.25 M sodium citrate solution. The vials were shaken mechanically for 12 hours at in orbital shaker (Khera Instrument Pvt. Ltd., India). The solutions were allowed to equilibrate for next 24 hours and then centrifuged for 5 min at 2000 rp m. The supernatant of each vial was filtered through Whatman filter paper # 41. Filtrates were diluted suitably and analyzed against corresponding solvent blanks. In this experiment mixed hydrotropy principle is applied in which to hydrotrops in different concentration were used for increasing the solubility of the drug for example 4 M s odium acetate and 1.25 M sodium citrate.
Analysis of Fenofi brate in tablets using 4 M sodi um acetate and 1.25 M sodium citrate soluti on 13 : Twenty tablets of formulat ion-I (FENOLIP) were weighed and powdered. Powder equivalent to 145 mg Fenofibrate was transferred to a 50 ml volu metric flask containing 40 ml of 4 M sodiu m acetate and 1.25 M sodium cit rate solution. The flask was shaken for about 5 min to solubilize the drug. Then volume was made up to the mark with distilled water. Solution was filtered through Whatman filter paper # 41. filtrate was divided in two parts, A and B. part A was kept at room temperature for 48 hours to check the effect on stability of drug in presence of sodium benzoate and also to note precipitation, if any, during this period. Pa rt B filtrate was appropriately diluted with distilled water and absorbance was noted at 296 n m (λ max ) against solvent blank and the drug content was calculated (Table-1) . After 48 hours, filtrate of part B was also appropriately diluted with distilled water and analyzed for drug content. There was no precipitation in the filtrate in 48 hours. Similar procedures were adopted in cases of formulation-II (STANLIP) and formu lation-III (LOTZL).
ABS TRACT
A sensitive and rapid extractive spectrophotometer method has been developed for the assay of Fenofibrate in bulk drug and tablets. Fenofibrate shows maximum absorbance at 296 nm. Beer's law was obeyed in the concentration range of in the range of 5-35µg/ml. Beers law was obeyed in this concentration range with correlation coefficient of 0.999. The concentrations of this drug were evaluated in laboratory mixture and marketed formulation. Accuracy was determined by recovery studies from tablet dosages forms and ranges from 99.33 -100.92 %. Precision of method was find out as repeatability, day to day and analyst to analyst variation and shows the values within acceptable limit (R. Recovery studies are performed by adding extra bulk d rug nearly forty percent of formu lations or more. For recovery studies, tablet powder of formu lation I ((FENOLIP) equivalent to 145 mg drug was taken in a 25 ml volu metric flask. In this flask 70 mg of pure drug (corresponding spiked drug) was transferred and 20 ml of 4 M sodium acetate and 1.25 M sodium citrate solutions were added and the flask was shaken for about 10 min. Then volume was made upto the mark with distilled water and filtered through Whatman filter paper # 41. The solution was diluted appropriately with distilled water and analyzed for drug content. Simila r procedures were adopted for formulat ion II (STANLIP) & formulat ion III (LOTZL).
The results of analysis of recovery studies are presented in (Table 2) (Table  2) . Thus, the proposed method of analysis was very well validated. 
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